← board
TWST
distress 1/10 · well-funded / low risk$95.13+1%today-8% from 52w high
Revenue
pre-revenue
Liquidity
$202M
Runway
4.3 yrs
Shares 1y
+3%
Price & events
+110.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.0%
1D
+4.3%
1W
+11.9%
1M
+61.6%
3M
+121.5%
6M
+164.0%
1Y
+61.6%
2Y
-18.9%
5Y
-28.4%
All
Overview
- Market Cap
- $5.92B
- Volume
- 120.91K
- 52 Week Range
- $24.16 – $103
- Total Shares
- 62.27M
- Float Shares
- 55.37M
- Short %
- 28.74%
- % Held by Insiders
- 1.20%
- % Held by Institutions
- 124.30%
- RVOL
- 0.07x
- Beta
- 2.12
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2026-08-03Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-02-11partnershipTwist enters license agreement with Invenra, acquiring technology and taking ~6% equity stake.SEC 8-K
- 2025-05-02partnershipTwist Bioscience spun out its DNA data storage application as Atlas Data Storage with $155M investment.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $89 (-7% upside) · 10 analysts
- 2026-07-14Canaccord GenuityBuy
- 2026-07-06Evercore ISI GroupOutperform → In-Line
- 2026-06-29GuggenheimBuy
- 2026-06-24BarclaysOverweight
- 2026-06-15TD CowenBuy
- 2026-06-15Canaccord GenuityBuy
Competitors
- none identified
Recent news
- 2026-07-21ETFs Investing in Twist Bioscience Corp. Stocks - TradingView
- 2026-07-21Twist Bioscience Corp Investor Day Transcript - GuruFocus
- 2026-07-17Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $110 - 富途牛牛
- 2026-07-16Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $110 - Moomoo
- 2026-07-16Why is Piper Sandler Bullish on Twist Bioscience (TWST) - Kavout | AI
- 2026-07-15Twist Bioscience plans 8 a.m. ET call for fiscal Q3 update - Stock Titan
- 2026-07-14TWST Maintained by Canaccord Genuity -- Price Target Raised to $120 - GuruFocus
- 2026-07-14Form 4 Twist Bioscience Corp For: 13 July By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.